Listed

Propanc Biopharma, Inc.: Form 10-K for the period ended Jun 30, 2014

Filed with the SEC on Oct 14, 2014 and accepted by EDGAR at Oct 14, 2014, 16:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2013-07-01 to 2014-06-30$8.2kus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2013-07-01 to 2014-06-30−$761.2kus-gaap:OperatingIncomeLoss
Interest expense12 months2013-07-01 to 2014-06-30$93.1kus-gaap:InterestExpense
Income tax12 months2013-07-01 to 2014-06-30−$48.3kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2013-07-01 to 2014-06-30−$829.6kus-gaap:NetIncomeLoss
Diluted EPS12 months2013-07-01 to 2014-06-30−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2013-07-01 to 2014-06-30$226.4kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2014-06-30$87.8kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-06-30$113.7kus-gaap:AssetsCurrent
Total assetsAt period end2014-06-30$113.7kus-gaap:Assets
Current liabilitiesAt period end2014-06-30$1.5mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2014-06-30−$1.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-14-060984. Last ingested by Listed: Nov 14, 2026, 18:42 ET. Listed shows no prices and gives no investment advice.